Fox News medical contributor Dr. Nicole Saphier discuses top headlines relating to health and wellness on ‘Fox & Friends Weekend.’

As a physician, I have witnessed countless medical breakthroughs that have transformed patient care and improved lives. One such innovation is the advent of GLP-1 agonists, a class of medications initially developed to treat type 2 diabetes but have since gained unprecedented popularity for their efficacy in weight loss.

These drugs, such as semaglutide, have garnered attention for their ability to help people shed significant amounts of weight, improve blood sugar control, and reduce the risk of cardiovascular disease. However, while the benefits are undeniable, the rapid adoption of these medications raises concerns about potential long-term consequences, dependency, and the broader implications for our relationship with food and health.

GLP-1 agonists work by mimicking the action of the hormone glucagon-like peptide-1, which increases insulin secretion, decreases glucagon release and slows gastric emptying. This results in reduced appetite, increased satiety, and improved glycemic control, making these medications incredibly effective for weight loss and managing diabetes.

For individuals who have struggled with weight loss through diet and exercise alone, these medications offer hope and a tangible solution. (Joel Saget/AFP via Getty Images)

Clinical trials have shown that patients on these medications can lose up to 15-20% of their body weight, a result previously achievable only through bariatric surgery.

DIABETES PATIENTS NOW HAVE ACCESS TO FIRST GENERIC GLP-1 MEDICATION: ‘MORE ACCESSIBLE AND AFFORDABLE’

The implications of this weight loss........

© Fox News